TLX vs. CAI

Last updated Jun 4, 2026

TLX (Telix Pharmaceuticals Ltd) and CAI (Caris Life Sciences, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.09 correlation, their price movements are largely independent.

Performance

TLX vs. CAI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Telix Pharmaceuticals Ltd (TLX) and Caris Life Sciences, Inc (CAI). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TLX achieves a 17.09% return, which is significantly higher than CAI's -42.62% return.

TLX

• 1D: -4.26%
• 1M: -21.35%
• YTD: 17.09%
• 6M: -9.21%
• 1Y: -48.32%
• 3Y*: —
• 5Y*: —
• 10Y*: —

CAI

• 1D: -6.30%
• 1M: -17.17%
• YTD: -42.62%
• 6M: -43.17%
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

TLX vs. CAI - Yearly Performance Comparison

	2026 (YTD)	2025
TLX Telix Pharmaceuticals Ltd	17.09%	-55.84%
CAI Caris Life Sciences, Inc	-42.62%	-3.64%

Correlation

The correlation between TLX and CAI is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (All Time) Calculated using the full available price history since Jun 20, 2025	0.09

Fundamentals

Market Cap TLX : $2.97B CAI : $4.37B
EPS TLX : $0.12 CAI : $0.05
PE Ratio TLX : 75.65 CAI : 287.88
PEG Ratio TLX : 0.09 CAI : 1.10
PS Ratio TLX : 1.48 CAI : 10.78
PB Ratio TLX : 4.77 CAI : 7.37
Total Revenue (TTM) TLX : $2.00B CAI : $907.29M
Gross Profit (TTM) TLX : $1.13B CAI : $482.11M
EBITDA (TTM) TLX : $153.71M CAI : $92.24M

Return for Risk

TLX vs. CAI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TLX

TLX Risk / Return Rank: 12
TLX Sharpe Ratio Rank: 8
TLX Sortino Ratio Rank: 9
TLX Omega Ratio Rank: 11
TLX Calmar Ratio Rank: 13
TLX Martin Ratio Rank: 17

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TLX vs. CAI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Telix Pharmaceuticals Ltd (TLX) and Caris Life Sciences, Inc (CAI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TLX	CAI	Difference
Sharpe ratio: Return per unit of total volatility	-0.83	—	—
Sortino ratio: Return per unit of downside risk	-1.19	—	—
Omega ratio: Gain probability vs. loss probability	0.86	—	—
Calmar ratio: Return relative to maximum drawdown	-0.77	—	—
Martin ratio: Return relative to average drawdown	-1.12	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	TLX	CAI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.83	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.53	-0.75	+0.22

Drawdowns

TLX vs. CAI - Drawdown Comparison

The maximum TLX drawdown since its inception was -69.37%, which is greater than CAI's maximum drawdown of -62.98%. Use the drawdown chart below to compare losses from any high point for TLX and CAI.

Drawdown Indicators

	TLX	CAI	Difference
Max Drawdown Largest peak-to-trough decline	-69.37%	-62.98%	-6.39%
Max Drawdown (1Y) Largest decline over 1 year	-63.33%	—	—
Current Drawdown Current decline from peak	-58.10%	-60.61%	+2.51%
Average Drawdown Average peak-to-trough decline	-36.51%	-31.05%	-5.46%
Ulcer Index Depth and duration of drawdowns from previous peaks	43.36%	—	—

Volatility

Volatility by Period

	TLX	CAI	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.21%	—	—
Volatility (6M) Calculated over the trailing 6-month period	40.70%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	58.24%	62.20%	-3.96%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	57.09%	62.20%	-5.11%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	57.09%	62.20%	-5.11%

Dividends

TLX vs. CAI - Dividend Comparison

Neither TLX nor CAI has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

TLX vs. CAI - Profitability Comparison

The chart below illustrates the profitability comparison between Telix Pharmaceuticals Ltd and Caris Life Sciences, Inc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

TLX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Telix Pharmaceuticals Ltd reported a gross profit of 327.42M and revenue of 620.44M. Therefore, the gross margin over that period was 52.8%.

CAI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Caris Life Sciences, Inc reported a gross profit of 0.00 and revenue of 216.17M. Therefore, the gross margin over that period was 0.0%.

TLX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Telix Pharmaceuticals Ltd reported an operating income of 9.82M and revenue of 620.44M, resulting in an operating margin of 1.6%.

CAI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Caris Life Sciences, Inc reported an operating income of 5.28M and revenue of 216.17M, resulting in an operating margin of 2.4%.

TLX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Telix Pharmaceuticals Ltd reported a net income of -7.25M and revenue of 620.44M, resulting in a net margin of -1.2%.

CAI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Caris Life Sciences, Inc reported a net income of -510.00K and revenue of 216.17M, resulting in a net margin of -0.2%.

Frequently Asked Questions

Can I hold both TLX and CAI in my portfolio?

TLX and CAI have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.